Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108280 | 0.77 | MAPT (0.32) | ALDH1A1MAPTPOLBHTTGAA | |
| SCHEMBL10102727 | 0.76 | MAPT (0.36) | KDM4EALDH1A1MAPTL3MBTL1POLB | |
| SCHEMBL64091 | 0.75 | ALDH1A1 (0.42) | KDM4EALDH1A1MAPTL3MBTL1POLB | |
| SCHEMBL10102759 | 0.72 | KDM4E (0.43) | KDM4EALDH1A1MAPTL3MBTL1HTT | |
| SCHEMBL10108154 | 0.70 | KDM4E (0.34) | KDM4EALDH1A1L3MBTL1HTTATM | |
| SCHEMBL10108283 | 0.69 | KMT2A (0.35) | KDM4EALDH1A1MAPTL3MBTL1POLB | |
| SCHEMBL16882296 | 0.69 | ALDH1A1 (0.35) | KDM4EALDH1A1MAPTL3MBTL1POLB | |
| SCHEMBL11965415 | 0.69 | KDM4E (0.33) | KDM4EALDH1A1L3MBTL1ATMGAA | |
| SCHEMBL10102755 | 0.69 | KDM4E (0.33) | KDM4EALDH1A1L3MBTL1ATMGAA | |
| SCHEMBL7053245 | 0.68 | ALDH1A1 (0.41) | KDM4EALDH1A1MAPTL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | KDM4E 724/4885ALDH1A1 3257/4885MAPT 3315/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | KDM4E 667/4885ALDH1A1 3205/4885MAPT 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.